2017 AVAC Advocacy Fellow Peter Mogere speaks on Kenya’s KUTV about HIV self-testing.
Watch the clip (17:29).
AVAC Fellow Peter Mogere: HIV self-testing
Px Wire July-September 2017, Vol. 10, No. 3
This issue of AVAC’s quarterly newsletter, Px Wire, is now available. Check it out for a deep dive into the data that suggest men who have sex with men may be able protected by oral PrEP, even if they don’t dose every day—and for the reasons why these data do not apply to women. You’ll also find out why messages about global AIDS are on our mind—and what we’d change about the current global conversation.
Investment in HIV Prevention Research & Development
Because money matters as much as messages, this Px Wire centerspread summarizes current investments, and trends over time, in HIV-prevention research and development. This full-color feature is excerpted from the recently-released report on HIV prevention research and development investment produced by AVAC and partners in the field.
South African HIV Prevention Research and Demonstration Sites
South Africa’s Trial Sites: An overview of HIV prevention research and demonstration sites in 2017, by location and intervention.
Evolving Context for HIV Prevention Research (Map)
A global map showing selected HIV prevention research and oral PrEP status.
Fighting HIV Drug Resistance in Uganda
AVAC Fellow Moses Supercharger has this primer on the upward trend of HIV drug resistance in Uganda, with action items for advocates.
Global HIV Prevention R&D Investment by Technology Category, 2000-2016
In 2016, funding for HIV prevention R&D decreased by 3 percent (US$35 million) from the previous year, falling to US$1.17 billion. Funding in 2016 signals the lowest annual investment in HIV prevention R&D in more than a decade.
Composition of the Global HIV Prevention R&D Investment Base, 2015-2016
The call for a more diverse base of funders in the prevention R&D landscape is not a new one, but recent trends display greater polarization and a more extreme funding imbalance. In 2016, 75 percent of the overall funding came from the US public sector. Together, the US public sector and the BMGF represented 88 percent of the total global investment in 2016, compared to 81 percent in 2015.
Excerpted from our HIV prevention research tracking report, visit here for all graphics from the report.
HIV Prevention R&D Trial Participants by Region, 2016
HIV prevention research cannot be conducted without those who volunteer to participate in clinical trials or without the engagement of communities in which those trials take place. In 2016, there were almost 700,000 participants in HIV prevention research trials, primarily based in sites with high HIV/AIDS burdens in Africa, Asia, Latin America and the US.
Excerpted from our HIV prevention research tracking report, visit here for all graphics from the report.
HIV Prevention Research & Development Investments, 2000–2016: Investment priorities to fund innovation in a challenging global health landscape
This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2016, funding for HIV prevention R&D decreased by US$35 million from the previous year to a total of US$1.17 billion. This marks the lowest recorded annual investment in more than a decade. While investments toward research in preventive vaccines, PrEP and medical male circumcision increased in 2016, funding for microbicides, treatment as prevention, female condoms and prevention of vertical transmission decreased.